Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

BioMEL : a translational research biobank of melanocytic lesions and melanoma

Helkkula, Teo LU ; Christensen, Gustav LU ; Ingvar, Christian LU ; Isaksson, Karolin LU ; Harbst, Katja LU orcid ; Persson, Bertil LU ; Ingvar LU orcid ; Hafström, Anna LU ; Carneiro, Ana LU orcid and Gaspar, Viktoria LU , et al. (2024) In BMJ Open 14(2).
Abstract

Introduction Diagnosing invasive cutaneous melanoma (CM) can be challenging due to subjectivity in distinguishing equivocal nevi, melanoma in situ and thin CMs. The underlying molecular mechanisms of progression from nevus to melanoma must be better understood. Identifying biomarkers for treatment response, diagnostics and prognostics is crucial. Using biomedical data from biobanks and population-based healthcare data, translational research can improve patient care by implementing evidence-based findings. The BioMEL biobank is a prospective, multicentre, large-scale biomedical database on equivocal nevi and all stages of primary melanoma to metastases. Its purpose is to serve as a translational resource, enabling researchers to uncover... (More)

Introduction Diagnosing invasive cutaneous melanoma (CM) can be challenging due to subjectivity in distinguishing equivocal nevi, melanoma in situ and thin CMs. The underlying molecular mechanisms of progression from nevus to melanoma must be better understood. Identifying biomarkers for treatment response, diagnostics and prognostics is crucial. Using biomedical data from biobanks and population-based healthcare data, translational research can improve patient care by implementing evidence-based findings. The BioMEL biobank is a prospective, multicentre, large-scale biomedical database on equivocal nevi and all stages of primary melanoma to metastases. Its purpose is to serve as a translational resource, enabling researchers to uncover objective molecular, genotypic, phenotypic and structural differences in nevi and all stages of melanoma. The main objective is to leverage BioMEL to significantly improve diagnostics, prognostics and therapy outcomes of patients with melanoma. Methods and analysis The BioMEL biobank contains biological samples, epidemiological information and medical data from adult patients who receive routine care for melanoma. BioMEL is focused on primary and metastatic melanoma, but equivocal pigmented lesions such as clinically atypical nevi and melanoma in situ are also included. BioMEL data are gathered by questionnaires, blood sampling, tumour imaging, tissue sampling, medical records and histopathological reports. Ethics and dissemination The BioMEL biobank project is approved by the national Swedish Ethical Review Authority (Dnr. 2013/101, 2013/339, 2020/00469, 2021/01432 and 2022/02421-02). The datasets generated are not publicly available due to regulations related to the ethical review authority. Trial registration number NCT05446155.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cancer genetics, dermatological tumours, dermatopathology, diagnostic imaging, health informatics
in
BMJ Open
volume
14
issue
2
article number
e069694
publisher
BMJ Publishing Group
external identifiers
  • pmid:38309755
  • scopus:85184003657
ISSN
2044-6055
DOI
10.1136/bmjopen-2022-069694
language
English
LU publication?
yes
id
964fb0ee-fe82-4f17-951b-d7a1e2574123
date added to LUP
2024-03-06 15:08:13
date last changed
2024-04-18 15:55:48
@article{964fb0ee-fe82-4f17-951b-d7a1e2574123,
  abstract     = {{<p>Introduction Diagnosing invasive cutaneous melanoma (CM) can be challenging due to subjectivity in distinguishing equivocal nevi, melanoma in situ and thin CMs. The underlying molecular mechanisms of progression from nevus to melanoma must be better understood. Identifying biomarkers for treatment response, diagnostics and prognostics is crucial. Using biomedical data from biobanks and population-based healthcare data, translational research can improve patient care by implementing evidence-based findings. The BioMEL biobank is a prospective, multicentre, large-scale biomedical database on equivocal nevi and all stages of primary melanoma to metastases. Its purpose is to serve as a translational resource, enabling researchers to uncover objective molecular, genotypic, phenotypic and structural differences in nevi and all stages of melanoma. The main objective is to leverage BioMEL to significantly improve diagnostics, prognostics and therapy outcomes of patients with melanoma. Methods and analysis The BioMEL biobank contains biological samples, epidemiological information and medical data from adult patients who receive routine care for melanoma. BioMEL is focused on primary and metastatic melanoma, but equivocal pigmented lesions such as clinically atypical nevi and melanoma in situ are also included. BioMEL data are gathered by questionnaires, blood sampling, tumour imaging, tissue sampling, medical records and histopathological reports. Ethics and dissemination The BioMEL biobank project is approved by the national Swedish Ethical Review Authority (Dnr. 2013/101, 2013/339, 2020/00469, 2021/01432 and 2022/02421-02). The datasets generated are not publicly available due to regulations related to the ethical review authority. Trial registration number NCT05446155.</p>}},
  author       = {{Helkkula, Teo and Christensen, Gustav and Ingvar, Christian and Isaksson, Karolin and Harbst, Katja and Persson, Bertil and Ingvar and Hafström, Anna and Carneiro, Ana and Gaspar, Viktoria and Jönsson, Göran and Nielsen, Kari}},
  issn         = {{2044-6055}},
  keywords     = {{cancer genetics; dermatological tumours; dermatopathology; diagnostic imaging; health informatics}},
  language     = {{eng}},
  number       = {{2}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{BMJ Open}},
  title        = {{BioMEL : a translational research biobank of melanocytic lesions and melanoma}},
  url          = {{http://dx.doi.org/10.1136/bmjopen-2022-069694}},
  doi          = {{10.1136/bmjopen-2022-069694}},
  volume       = {{14}},
  year         = {{2024}},
}